Serum ischemia-modified albumin level returns to its premenopausal level
with 1-year hormone therapy in healthy menopausal women

Esra Can Cetin; Suleyman Guven; Hidayet Sal; Emine Seda Guvendag Guven; Ahmet Mentese

doi:10.5114/pm.2021.106089

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2021
vol. 20

Send email

Copy url:

abstract:

Original paper

Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women

Esra Can Cetin

¹

,

Suleyman Guven

¹

,

Hidayet Sal

¹

,

Emine Seda Guvendag Guven

¹

,

Ahmet Mentese

²

Karadeniz Technical University School of Medicine, Department of Obstetrics and Gynecology, Trabzon, Turkey
Program of Medical Laboratory Techniques, Vocational School of Health Sciences, Karadeniz Technical University, Trabzon, Turkey

Menopause Rev 2021; 20(2): 76-80

DOI: https://doi.org/10.5114/pm.2021.106089

Online publish date: 2021/05/23

View full text Get citation

PlumX metrics:

Introduction
To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women.

Material and methods
Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate).

Results
The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy.

Conclusions
These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months’ use, serum IMA levels returned to baseline levels after 12 months’ use. Based on this study’s findings, long‑term use of HT may not have a positive effect on cardiovascular disease protection.

keywords:

Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women

Esra Can Cetin 1 , Suleyman Guven 1 , Hidayet Sal 1 , Emine Seda Guvendag Guven 1 , Ahmet Mentese 2

IMA, menopause, hormone therapy, cardiovascular risk

Esra Can Cetin

¹

,

Suleyman Guven

¹

,

Hidayet Sal

¹

,

Emine Seda Guvendag Guven

¹

,

Ahmet Mentese

²